In vitro and in vivo evaluation of sustained release hydralazine hydrochloride tablets prepared by thermal granulation technique

Australian Journal of Basic and Applied Sciences

Volumn 3, Issue 3, 2009, Pages 2866-2875

  Al Suwayeh, Aleh A ^a   El Shaboury, Mohammed H ^a   Al Baraki, Saeed M ^a   Elgorashy, Abubakar S ^a   Taha, Ehab I ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

DSC and bioavailability; Hydralazine hydrochloride; Thermal granulation

Indexed keywords

EID: 77952255856     PISSN: 19918178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ansari, M.A. and F. Stepanek, 2006. Formation of hollow core granules by fluid bed in situ melt granulation: modelling and experiments. International Journal of Pharmaceutics, 321: 108-116.
2. Bayomi, M.A., A.A. Al-Angary, M.A. Al-Meshal and G.M. El-Mahrouk, 1994. Preparation and dissolution characteristics of prolonged release mebeverin hydrochloride beads. Drug development and Industrial Pharmacy, 20: 2763-2773.
3. Boon, N., G.H. Goossens, E.E. Blaak and W.H. Saris, 2007. The effects of hydralazine on lipolysis in subcutaneous adipose tissue in humans. Metabolism, 56: 1742-1748.
4. Bultmann, J.M., 2002. Multiple compaction of microcrystalline cellulose in a roller compactor. European Journal of Pharmaceutics and Biopharmaceutics, 54: 59-64.
5. Chambin, O. and V. Jannin, 2005. Interest of multifunctional lipid excipients: case of Gelucire 44/14. Drug development and Industrial Pharmacy, 31: 527-534.
6. Chen, Y.J., S.M. Huang, C.Y. Liu, P.H. Yeh and T.H. Ts ai, 2008. Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. International Journal of Pharmaceutics, 50: 230-239.
7. Chen, C., 2007. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. The Drugs in R and D, 8: 301-314.
8. Colombo, P., R. Bettini, G. Massimo, P.L. Catellani, P. Santi and N.A. Peppas, 1995. Drug diffusion front movement is important in drug releasae control from swellable matris tablets. Journal of Pharmaceutical Sciences, 84: 991-997.
9. Colombo, P., U. Conte, A. Gazzaniga, L. Maggi, M.E. Sangalli, N.A. Peppas, and I. Manna, 1990. Drug release modulation by physical restrictions of matrix swelling. International Journal of Pharmaceutics, 63: 43-48.
10. Escudero, J.J., C. Ferrero and M.R. Jimenez-Castellanos, 2008. Compaction properties, drug release kinetics and fronts movement studies from matrices combining mixtures of swellable and inert polymers: Effect of HPMC of different viscosity grades. International Journal of Pharmaceutics, 351: 61-73.
11. Fell, J.T. and J.M. Newton, 1970. Determination of tablet strength by the diametral compression test. Journal of Pharmaceutical Sciences, 59: 688-691.
12. Forni, F., G. Coppi, M.A. Vandelli and M.T. Bernabei, 1990. An interpretation of the diffusion type mechanism of drug release from microcapsules. International Journal of Pharmaceutics, 60: 83-88
13. Goole, J., P. Deleuze, F.Vand erbist and K. Amighi, 2008. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. European Journal of Pharmaceutics and Biopharmaceutics, 68: 310-318.
14. Iwaki, M., T. Ogiso and Y. Ito, 1989. Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat. Journal of Pharmaceutical Sciences, 78: 867-873
15. Kirsten, R., K. Nelson, D. Kirsten and B. Heintz, 1998. Clinical pharmacokinetics of vasodilators. Part II. Clinical Pharmacokinetics, 35: 9-36.
16. Khan, G.M. and V.M. Meidan, 2007. Drug release kinetics from tablet matrices based upon ethylcellulose ether-derivatives: a comparison between different formulations. Drug development and Industrial Pharmacy, 33: 627-639.
17. Lessen, T. and D.C. Zhao, 1996. Interactions between drug substances and excipients. 1. Fluorescence and HPLC studies of triazolophthalazine derivatives from hydralazine hydrochloride and starch. Journal of Pharmaceutical Sciences, 85: 326-329.
18. Martelli, A., A. Allavena, G.B. Campart, R. Canonero, M. Ghia, F. Mattioli, E. Mereto, L. Robbiano and G. Brambilla, 1995. In vitro and in vivo testing of hydralazine genotoxicity. Journal of Pharmacology and Experimental Therapeutics, 273: 113-120.
19. Lacey, L.F., O.N. Keene, C. Duquesnoy and A. Bye, 1997. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. International Journal of Pharmaceutics, 86: 401- 402.
20. Ludden, T.M., A.M. Shepherd, J.L. McNay and M.S. Lin, 1980. Hydralazine kinetics in hypertensive patients after intravenous administration. Clinical Pharmacology and Therapeutics, 28: 736-742
21. Ochoa, L., M. Igartua, R.M. Hernandez, A.R. Gascon and J.L. Pedraz, 2005. Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer. Journal of Pharmacy and Pharmaceutical Sciences, 8: 132-140.
22. Passerini, N., B. Albertini, B. Perissutti and L. Rodriguez, 2006. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. International Journal of Pharmaceutics, 318: 92-102.
23. Proveaux, W.J., J.P. O'Donnell and J.K. Ma, 1979. Liquid chromatographic analysis of hydralazine and metabolites in plasma. Journal of Chromatography, 176: 480-484.
24. Ranga Rao, K.V. and K. Padmalatha Devi, 1988. Swelling controlled release systems: Recent development and applications. International Journal of Pharmaceutics, 48: 1-13.
25. Sandhu, H.K., A. Chatterji, N.H. Shah, A.W. Malick, D. Desai and H. Zia, 2007. Effect of formulation and processing variables on the granulation kinetics of hot melt granulation (HMG) process. Pharmaceutical Development and Technology, 12: 145-151.
26. Salsa, T., F. Veiga and M.E. Pina, 1997. Oral controlled releas e dos age forms: I. Cellulose ether polymers in hydrophilic matrices. Drug development and Industrial Pharmacy, 239: 929-938
27. Semple, H.A., Y.K. Tam and R.T. Coutts, 1990. Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. Pharmaceutical Research, 7: 274-279.
28. Siegmund, W., M. Zschiesche, L. Schroder, G. Franke, E. Udvary and H. Huller, 1987. Pharmacokinetics of dihydralazine following intravenous administration in laboratory animals. Pharmazie., 42: 527-530
29. Saker, A.M., A.A. Kassem, S.A. Aziz and A.H. Shalaby, 1973. Factors affecting the physical standards of pharmaceutical tablets. Canadian Journal of Pharmaceutical Sciences, 8: 6-12.
30. Salsa, T., F. Veiga and M.E. Pina, 1997. Oral controlled release dosage forms. I. Cellulos e ether polymers in hydrophilic matrices. Drug development and Industrial Pharmacy, 23: 929-938.
31. Sintov, A.C. and S. Botner, 2006. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin s torage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. International Journal of Pharmceutics, 311: 55-62.
32. Schall, R. and H.G. Luss, 1992. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 30: 153-159.
33. Sujja-Areevath, J., D.L. Munday, P.J. Cox and K.M. Khan, 1998. Relationship between swelling, erosion and drug release in hydrophilic natural gum mini-matrix formulation. European Journal of Pharmaceutical Sciences, 6: 207-217.
34. Uhumwangho, M.U. and R.S. Okor, 2006. Studies on the compressibility of wax matrix granules of acetaminophen and their admixtures with various tableting bases. Pakistani Journal of Pharmaceutical Sciences, 19: 103-107.
35. Yang, D., R. Kulkarni, R.J. Behme and P.N. Kotiyan, 2007. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. International Journal of Pharmaceutics, 329: 72-80
36. Van Melkebeke, B., B. Vermeulen, C. Vervaet and J.P. Remon, 2006. Melt granulation using a twin-screw extruder: a case study. International Journal of Pharmaceutics, 326: 89-93.
37. Zhang, L., Z. Zuo and G. Lin, 2007. Intestinal and hepatic glucuronidation of flavonoids. Molecular Pharmaceutics, 4: 833-845.